| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Euphorbia Factor L2 targets inflammatory pathways and cancer cells. Its anti-inflammatory activity involves modulation of inflammatory mediators. The compound's anticancer activity involves induction of apoptosis and inhibition of cell proliferation. Its mechanism may involve modulation of signaling pathways such as NF-κB and MAPK.
|
|---|---|
| ln Vitro |
Euphorbia Factor L2 demonstrates in vitro anti-inflammatory and anticancer activities. It inhibits the proliferation of cancer cell lines and induces apoptosis. The compound's anti-inflammatory activity is demonstrated by its ability to reduce the production of inflammatory mediators in activated immune cells.
|
| ln Vivo |
In vivo activity of Euphorbia Factor L2 has been suggested by its anti-inflammatory and anticancer properties. Further in vivo studies are needed to evaluate its pharmacokinetic properties, efficacy, and safety profile.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Euphorbia Factor L2 are not extensively documented. Its anti-inflammatory activity can be assessed by measuring cytokine production. Anticancer activity is assessed using cell viability assays against cancer cell lines.
|
| Cell Assay |
In vitro cellular assays for Euphorbia Factor L2 involve treating cancer cell lines or immune cells with varying concentrations of the compound. Cell viability is assessed using MTT or other assays. Apoptosis is evaluated by Annexin V staining or caspase activity assays. Anti-inflammatory activity is assessed by measuring cytokine production.
|
| Animal Protocol |
In vivo animal experiments for Euphorbia Factor L2 would typically involve administering the compound to animal models of cancer or inflammation. Efficacy is evaluated by measuring tumor growth inhibition, inflammatory markers, or clinical outcomes.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Euphorbia Factor L2 are limited. The compound has a molecular weight of 496.64 and a molecular formula of C30H40O6. Its absorption, distribution, metabolism, and excretion properties have not been fully characterized.
|
| Toxicity/Toxicokinetics |
Toxicological data for Euphorbia Factor L2 are limited. As a natural product-derived compound, it is generally considered to have low toxicity, but comprehensive toxicological studies have not been reported.
|
| References | |
| Additional Infomation |
It has been reported that plants of the Euphorbia genus contain [(1R,3Z,5R,7S,9R,11R,12R,13S,14S)-1,11-diacetoxy-13-benzoyloxy-3,6,6,14-tetramethyl-10-methylene-2-oxo-9-tricyclic[10.3.0.05,7]pentadecano-3-enyl]benzoate, and relevant data are available.
Euphorbia Factor L2 (CAS#: 218916-51-9) has the molecular formula C30H40O6 and a molecular weight of 496.64. It is a diterpenoid natural product with anti-inflammatory and anticancer activities. It is for research use only. |
| Molecular Formula |
C38H42O9
|
|---|---|
| Molecular Weight |
642.73
|
| Exact Mass |
642.282
|
| CAS # |
218916-51-9
|
| PubChem CID |
101071473
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
697.6±55.0 °C at 760 mmHg
|
| Flash Point |
284.6±31.5 °C
|
| Vapour Pressure |
0.0±2.2 mmHg at 25°C
|
| Index of Refraction |
1.582
|
| LogP |
8.36
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
47
|
| Complexity |
1300
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C[C@H]1C[C@]2([C@H]([C@H]1OC(=O)C3=CC=CC=C3)[C@H](C(=C)[C@@H](C[C@H]4[C@H](C4(C)C)/C=C(\C2=O)/C)OC(=O)C5=CC=CC=C5)OC(=O)C)OC(=O)C
|
| InChi Key |
AFRGWGGHJYMSDU-NKGNXCQNSA-N
|
| InChi Code |
InChI=1S/C38H42O9/c1-21-18-28-29(37(28,6)7)19-30(45-35(42)26-14-10-8-11-15-26)23(3)33(44-24(4)39)31-32(46-36(43)27-16-12-9-13-17-27)22(2)20-38(31,34(21)41)47-25(5)40/h8-18,22,28-33H,3,19-20H2,1-2,4-7H3/b21-18-/t22-,28+,29-,30+,31+,32-,33-,38+/m0/s1
|
| Chemical Name |
[(1R,3Z,5R,7S,9R,11R,12R,13S,14S)-1,11-diacetyloxy-13-benzoyloxy-3,6,6,14-tetramethyl-10-methylidene-2-oxo-9-tricyclo[10.3.0.05,7]pentadec-3-enyl] benzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 83.33 mg/mL (129.65 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 6.25 mg/mL (9.72 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 62.5 mg/mL clear DMSO stock solution to 900 μL corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5559 mL | 7.7793 mL | 15.5586 mL | |
| 5 mM | 0.3112 mL | 1.5559 mL | 3.1117 mL | |
| 10 mM | 0.1556 mL | 0.7779 mL | 1.5559 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
